Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

211: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo - Part 1

Dec 2, 2025

In this engaging conversation, Jesús Zurdo, a biotech scientist with nearly 30 years of experience and a leukemia survivor, shares unique insights on merging innovation with patient access. He emphasizes the need for patient-centered product design right from the start and discusses the balance between urgency and safety in manufacturing. Jesús challenges the biotech industry’s focus on costs over access and advocates for quality that is fit-for-purpose. He also explores alternative pricing models and the importance of real-world patient outcomes in therapy development.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Scale Up Is About Patients, Not Volume

Scaling up means increasing the number of patients reached, not just liters or cell counts.
Consider patient access, location, and affordability when designing manufacturing strategies.

ADVICE

Prioritize Safety While Acting With Urgency

Do not equate patient urgency with cutting corners; maintain safety and manufacturing confidence.
Balance speed with robust processes so effective products can be scaled and safely delivered.

ANECDOTE

Rapid Point‑Of‑Care Cell Delivery

Jesús Zurdo received living donor cells at his bedside within 48 hours after an apheresis in the U.S.
Point-of-care stem cell logistics worked reliably across countries with limited infrastructure.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Real progress in cell and gene therapy shouldn’t be measured solely by scientific innovation, but by whether those innovations actually reach the patients who need them most.

In this episode, David Brühlmann sits down with Jesús Zurdo, a scientist who’s spent three decades engineering life-changing biotechnologies, but whose outlook on the field shifted dramatically after becoming a leukemia patient himself.

With experience on both sides of the system, Jesús Zurdo brings a rare, unfiltered perspective to the persistent gap between scientific promise and real-world patient access.

Here’s why this conversation will reshape the way you think about bioprocessing, scale-up, and the meaning of “patient-centric” innovation:

The challenges of scaling up advanced therapies beyond just volume: shifting from “how much can we make” to “how many patients can we reach?” (00:21)
Jesús Zurdo’s personal journey—from biotech innovator to patient—and how it reshaped his thinking on product design and patient needs (04:12)
How the biotech industry often overemphasizes automation, cost of goods, and new technologies at the expense of true patient access (08:02)
The importance of designing products and manufacturing processes with patients’ lived experience in mind—not just clinical metrics (05:43)
Why the business model and value proposition of therapies may need to change to address the high cost and limited accessibility of new treatments (12:09)
Lessons from point-of-care manufacturing and real-world delivery of cell therapies—speed versus perfection (09:11)
How patient involvement in both development and long-term outcome tracking could drive better treatments and wider adoption (15:10)
The limitations of current clinical trial endpoints and the need to integrate patient-reported outcomes and new data sources like wearables (17:10)

Real progress in biotech isn’t just about scientific breakthroughs, it’s about ensuring those advances reach the millions who need them most.

Let’s rethink our business models and deployment strategies to bridge this gap for real-world impact

Connect with Jesús Zurdo:

LinkedIn: https://www.linkedin.com/in/jesuszurdo

Email: jesus.zurdo@gmail.com

Next step:

Need fast CMC guidance? New on-demand CMC advisory → Learn more here

Support the show